FINAL SYNTHESIS REPORT

SCOPE 2026

From Innovation Theater to Operational Excellence

All the Strategic intelligence clinical operations leaders need to succeed. Discover how top sponsors are treating AI as infrastructure, simplifying protocols, rebuilding oversight for distributed trials, and leveraging strategic FSP models to accelerate development timelines.

📍 Orlando, Florida | February 3–5, 2026

📥 Download Full Report 📞 Schedule Consultation

$2.6B

Average Development Cost

255%

Digital Enrollment Acceleration

25%

Industry TMF Defect Rate

40%

Cost Savings (Hybrid FSP Model)

The Five Strategic Imperatives

Move AI from Innovation to Infrastructure

Stop treating AI as isolated pilots. Top sponsors are consolidating to 2-3 platforms, building validation frameworks once, and scaling across indications. The barrier is AI governance, not technology.

Simplify Protocols Systematically

Protocol complexity directly impacts enrollment speed and patient retention. Collect only what drives decisions. Data minimization is not cutting corners; it is a strategic focus that improves outcomes and reduces burden.

Rebuild Oversight for Distributed Trials

Hybrid and decentralized trials require new oversight models. Choose vendor consolidation, oversight platforms, or embedded FSP, or adopt a hybrid approach combining platforms and embedded teams for real-time visibility and control.

Integrate Cross-Functional Teams Early

Eliminate operational silos to drive coordinated execution. Involve PV, biostatistics, data management, and clinical operations early in protocol design. Integrated teams detect safety signals earlier, reduce queries, and improve site-preparedness.

Rethink Build-vs.-Buy with Strategic FSP

Purpose-built FSP providers show single-digit attrition versus 20–30% in traditional CRO models. Own core operations, data management, and strategy. Leverage FSP partners for therapeutic expertise, scalable capacity, and embedded continuity.

Four Critical Insights From SCOPE 2026

INSIGHT 1

Measurable Complexity

Protocol complexity is now quantifiable and optimizable. AbbVie's framework proves complexity directly impacts enrollment speed and patient withdrawal.

INSIGHT 2

25% Defect Rate

Only 55% of documents are “right first time.” AI-powered TMF solutions can materially reduce defects and minimize cascading regulatory risks.

INSIGHT 3

Digital Recruitment Wins

Video-based digital ads are 40% more cost-effective and reach vulnerable populations that traditional sites never see. Enrollment acceleration of 255% has been demonstrated.

INSIGHT 4

Governance is the Gap

Fewer than 25% of sponsors scale AI beyond pilots. The primary barriers are change management, validation burden, and integration complexity, not technology.

The 90-Day Action Plan

Days 1–30: Diagnostic & Alignment

Inventory current AI tools and integration gaps
Run a quality assessment on your eTMF (defect rates)
Map oversight gaps for all hybrid/DCT trials
Evaluate current build-vs-buy-vs-FSP capabilities

Days 31–60: Pilot & Validate

Launch 1–2 targeted AI pilots (TMF, recruitment, forecasting)
Implement protocol simplification on new Phase 2/3 trials
Test cross-functional integration with monthly study meetings
Deploy an FSP pilot for quick wins

Days 61–90: Scale & Implement

Scale validated AI pilots across your portfolio
Establish a governance framework for AI utilization
Launch an oversight model for your hybrid trials
Finalize your FSP partnerships and SOPs

Ready to Drive Operational Excellence?

Get the complete SCOPE 2026 synthesis report and join leading clinical operations professionals implementing these five strategic imperatives.